2006
DOI: 10.1161/circulationaha.106.644583
|View full text |Cite
|
Sign up to set email alerts
|

Death, Cardiac Dysfunction, and Arrhythmias Are Increased by Calmodulin Kinase II in Calcineurin Cardiomyopathy

Abstract: Background-Activation of cellular Ca2ϩ signaling molecules appears to be a fundamental step in the progression of cardiomyopathy and arrhythmias. Myocardial overexpression of the constitutively active Ca 2ϩ -dependent phosphatase calcineurin (CAN) causes severe cardiomyopathy marked by left ventricular (LV) dysfunction, arrhythmias, and increased mortality rate, but CAN antagonist drugs primarily reduce hypertrophy without improving LV function or risk of death. Methods and Results-We found that activity and e… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

6
82
0

Year Published

2009
2009
2023
2023

Publication Types

Select...
6
3
1

Relationship

5
5

Authors

Journals

citations
Cited by 103 publications
(88 citation statements)
references
References 38 publications
6
82
0
Order By: Relevance
“…Our data in Ryr2 S2814A knockin mice suggest that phosphorylation of S2814 on RyR2 is the major, but presumably not the only, downstream target of CaMKII during AF evolution. CaMKII is a known proarrhythmic signal and a promising therapeutic target for prevention of ventricular arrhythmias and sudden death (57). Our new findings expand the impact and scope of these earlier studies by showing that CaMKII inhibition could be a new approach to treating AF.…”
Section: Figuresupporting
confidence: 64%
“…Our data in Ryr2 S2814A knockin mice suggest that phosphorylation of S2814 on RyR2 is the major, but presumably not the only, downstream target of CaMKII during AF evolution. CaMKII is a known proarrhythmic signal and a promising therapeutic target for prevention of ventricular arrhythmias and sudden death (57). Our new findings expand the impact and scope of these earlier studies by showing that CaMKII inhibition could be a new approach to treating AF.…”
Section: Figuresupporting
confidence: 64%
“…[16][17][18], transcription factors, and cell death pathways (19)(20)(21)(22). Finally, CaMKII inhibition has shown exciting promise for the treatment of excitable cell disease (5,(23)(24)(25)(26). Collectively, these data strongly support the notion that local CaMKII/effector signaling nodes represent key cellular rheostats to translate local alterations in the cellular environment to global changes in membrane excitability and organism function.…”
Section: Introductionmentioning
confidence: 61%
“…CaMKII has emerged as a core signaling molecule in contracting and pacemaking myocardial cells, because CaMKII catalyzes the phosphorylation of most major Ca 2+ homeostatic proteins (14) that orchestrate the mechanical force-frequency relationship (28) and enable fightor-flight increases in HR (4). Under disease conditions, excessive autonomous CaMKII activity can result from oxidation (29), and a growing body of evidence supports the concept that unconstrained and excessive CaMKII activity contributes to heart failure (12,30), arrhythmias (12,(30)(31)(32)(33)(34), and sudden death (35,36). CaMKII stimulation of apoptosis is an important component of the cardiomyopathic effects of excessive CaMKII activity (11,37,38).…”
Section: Discussionmentioning
confidence: 99%